Lamegom (Agomelatine)

Agomelatine works by stimulating melatonin MT1 and MT2 receptors, which helps reset the body’s circadian rhythm, and by blocking serotonin 5‑HT2C receptors, leading to increased dopamine and norepinephrine release in the frontal cortex. This combined action supports mood improvement and better sleep.

The prescribed dose of Lamegom is determined by the treating clinician based on individual patient factors, clinical response, and local prescribing guidelines. Typically, a starting dose of 25 mg taken once daily in the evening is used, with adjustments made only under medical supervision.

Safety data for agomelatine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the possible risk to the fetus or infant. Healthcare providers usually advise avoiding the medication during pregnancy and breastfeeding unless absolutely necessary.

To order Lamegom, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Unlike selective serotonin reuptake inhibitors (SSRIs), agomelatine targets melatonin receptors and blocks 5‑HT2C receptors, offering a unique mechanism that can improve sleep and circadian rhythm. It generally has a lower incidence of sexual dysfunction but requires liver function monitoring, which is less common with many SSRIs.

Lamegom tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct light, and ensure they are out of reach of children.

Lamegom is taken orally as a tablet, usually once daily in the evening, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and any food considerations.

The most serious risks include hepatotoxicity, which may present as elevated liver enzymes or liver injury, and the possible emergence or worsening of suicidal thoughts. Rare but severe reactions such as Stevens‑Johnson syndrome, severe allergic responses, and cardiac QT prolongation have also been reported.

Lamegom should not be used by patients with severe hepatic impairment, known hypersensitivity to agomelatine, or those taking strong CYP1A2 inhibitors such as fluvoxamine. It is also contraindicated in pregnancy unless the benefit outweighs the risk, and caution is advised in breastfeeding women.